As the US scales back its funding for global health research, a new study reveals that much of this money predominantly remains within wealthy countries. The research indicates that the resulting inventions are often later repurposed primarily for people in affluent, donor nations.
During Donald Trump’s second administration, significant changes occurred in the US approach to international health funding. Notably, the US Agency for International Development (USAID) was closed, and efforts were made to halt overseas sub-awards from the country’s National Institutes of Health (NIH).
These shifts raise important questions about the future of global health initiatives and the equitable distribution of medical advancements worldwide.
https://sciencebusiness.net/news/r-d-funding/drug-development/global-health-rd-benefits-rich-countries-too-study-argues
